Sotera Health (SHC) EBITDA Margin (2020 - 2026)
Sotera Health (SHC) posted EBITDA Margin of 34.17% for Q2 2026, up 21.34% on a QoQ basis from 28.16% in Q1 2026, and up 97.0% year-over-year from 17.34% in Q2 2025.
Powered by 
Analysis
Sotera Health (SHC) EBITDA Margin (2020 - 2026) Analysis & Trends
Sotera Health has reported EBITDA Margin for 7 years, with the latest figure at 34.17% in Q2 2026.
- On a quarterly basis, EBITDA Margin rose 97.0% year-over-year to 34.17% in Q2 2026; TTM through Jun 2026 was 33.82%, a 379.0% increase from a year earlier, with the FY2025 full-year figure at 33.75%, up 671.0% from the prior year.
- EBITDA Margin was 34.17% for Q2 2026 at Sotera Health, up from 28.16% in the prior quarter.
- The five-year high for EBITDA Margin was 36.7% in Q3 2025, with the low at 15.13% in Q1 2023.
- Average EBITDA Margin over 5 years is 28.05%, with a median of 28.18% recorded in 2024.
- The largest YoY upside for EBITDA Margin was 962 bps in 2023 against a maximum downside of 747 bps in 2023.
- Over 5 years, EBITDA Margin stood at 23.92% in 2022, then jumped by 40 bps to 33.53% in 2023, then decreased by 10 bps to 30.03% in 2024, then increased by 19 bps to 35.73% in 2025, then declined by 4 bps to 34.17% in 2026.
- The last three EBITDA Margin figures came in at 34.17% (Q2 2026), 28.16% (Q1 2026), and 35.73% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Natera | 49.39 Bn | 48.29 Bn | 486.15 Mn | -10.07% |
| 2 | Quest Diagnostics | 27.49 Bn | 26.86 Bn | 1.03 Bn | 15.08% |
| 3 | Labcorp Holdings | 26.51 Bn | 26.37 Bn | 1.11 Bn | 12.10% |
| 4 | Guardant Health | 23.17 Bn | 22.12 Bn | 219.03 Mn | -38.55% |
| 5 | Tempus AI | 12.59 Bn | 11.77 Bn | 274.25 Mn | -19.85% |
| 6 | Caris Life Sciences | 8.01 Bn | 7.22 Bn | 182.38 Mn | 10.21% |
| 7 | Sotera Health | 5.53 Bn | 5.17 Bn | 177.96 Mn | 34.17% |
| 8 | BillionToOne | 4.80 Bn | 4.25 Bn | 77.11 Mn | 5.03% |
| 9 | Adaptive Biotechnologies | 4.40 Bn | 4.05 Bn | 51.39 Mn | -22.04% |
| 10 | iRhythm Holdings | 3.68 Bn | 3.08 Bn | 163.21 Mn | -1.13% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 34.17% |
| Mar 31, 2026 | 28.16% |
| Dec 31, 2025 | 35.73% |
| Sep 30, 2025 | 36.70% |
| Jun 30, 2025 | 33.20% |
| Mar 31, 2025 | 28.43% |
| Dec 31, 2024 | 30.03% |
| Sep 30, 2024 | 28.20% |
| Jun 30, 2024 | 27.77% |
| Mar 31, 2024 | 21.43% |
| Dec 31, 2023 | 33.53% |
| Sep 30, 2023 | 28.92% |
| Jun 30, 2023 | 24.76% |
| Mar 31, 2023 | 15.13% |
| Dec 31, 2022 | 23.92% |
| Sep 30, 2022 | 25.41% |
| Jun 30, 2022 | 26.81% |
| Mar 31, 2022 | 22.59% |
| Dec 31, 2021 | 27.53% |
| Sep 30, 2021 | 29.04% |